| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10157964 | Vaccine | 2018 | 7 Pages |
Abstract
The cost-effectiveness of the PPV23 program in older Australians was estimated to have worsened over time. It is unlikely to have been cost-effective, unless PPV23 provided protection against non-invasive pneumococcal pneumonia and/or a low vaccine price was negotiated. A key policy priority should be to review of the future use of PPV23 in Australia, which is likely to be more cost-effective in certain high-risk groups.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
C. Chen, P. Beutels, J. Wood, R. Menzies, C.R. MacIntyre, P. McIntyre, A.T. Newall,